Cargando…

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

BACKGROUND: Poor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xueying, Xu, Jingxiao, Bi, Lixin, Liu, Peihao, Jiao, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678589/ https://www.ncbi.nlm.nih.gov/pubmed/34925245 http://dx.doi.org/10.3389/fendo.2021.790160

Ejemplares similares

Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria—The Why
por: Esteves, Sandro C., et al.
Publicado: (2018)

Reply: The low responder according to the POSEIDON criteria: is the prognosis really poor?
por: Leijdekkers, Jori A, et al.
Publicado: (2019)

Cumulative Live Birth Rates of Good and Low Prognosis Patients According to POSEIDON Criteria: A Single Center Analysis of 18,455 Treatment Cycles
por: Shi, Wenhao, et al.
Publicado: (2019)

Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection
por: Li, Yuan, et al.
Publicado: (2019)

Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study
por: Zhang, Shaodi, et al.
Publicado: (2021)

Follicular Output Rate and Follicle-to-Oocyte Index of Low Prognosis Patients According to POSEIDON Criteria: A Retrospective Cohort Study of 32,128 Treatment Cycles
por: Chen, Lijuan, et al.
Publicado: (2020)

An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria
por: Levi-Setti, Paolo Emanuele, et al.
Publicado: (2019)

Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria
por: Grynberg, Michael, et al.
Publicado: (2019)

The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists
por: Esteves, Sandro C., et al.
Publicado: (2019)

Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines
por: Esteves, Sandro C., et al.
Publicado: (2021)

Editorial: POSEIDON’s Stratification of ‘Low Prognosis’ Patients in ART: The WHY, the WHAT, and the HOW
por: Esteves, Sandro C., et al.
Publicado: (2021)

Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients
por: Esteves, Sandro C., et al.
Publicado: (2021)

The Effect of Growth Hormone on the Clinical Outcomes of Poor Ovarian Reserve Patients Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection Treatment: A Retrospective Study Based on POSEIDON Criteria
por: Cai, Mei-hong, et al.
Publicado: (2019)

Management Strategies for POSEIDON's Group 1
por: Polyzos, Nikolaos P., et al.
Publicado: (2019)

Management Strategies for POSEIDON Group 2
por: Sunkara, Sesh Kamal, et al.
Publicado: (2020)

Comparison of ART outcome in patients with poor ovarian response according to POSEIDON criteria
por: Lee, Hyun Joo, et al.
Publicado: (2022)

Management Strategies for POSEIDON Groups 3 and 4
por: Haahr, Thor, et al.
Publicado: (2019)

Future Perspectives of POSEIDON Stratification for Clinical Practice and Research
por: Humaidan, Peter, et al.
Publicado: (2019)

Commentary: Management Strategies for POSEIDON Groups 3 and 4
por: Bühler, Klaus F.
Publicado: (2020)

Commentary: Management Strategies for POSEIDON Groups 3 and 4
por: Fischer, Robert, et al.
Publicado: (2020)

Predictive Factors for Live Birth in Fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment in Poor Ovarian Reserve Patients Classified by the POSEIDON Criteria
por: Li, Fei, et al.
Publicado: (2021)

Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification
por: Grisendi, Valentina, et al.
Publicado: (2019)

Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study
por: Chen, Chunyan, et al.
Publicado: (2023)

The POSEIDON stratification - moving from poor ovarian response to low prognosis
por: Roque, Matheus, et al.
Publicado: (2021)

Cumulative live birth rates of patients in the Peruvian Andes according to the POSEIDON criteria: a single-center retrospective analysis
por: Vargas-Tominaga, Luis, et al.
Publicado: (2021)

Letrozole cotreatment improves the follicular output rate in high-body-mass-index women with polycystic ovary syndrome undergoing IVF treatment
por: Liu, Yali, et al.
Publicado: (2023)

The Livebirth Rate Per In Vitro Fertilization Cycle Is Higher Than The Cumulative Live Birth Rates of Intrauterine Insemination for Patients of Poseidon Group 3 With Unexplained Infertility
por: Wu, Yixuan, et al.
Publicado: (2021)

Criteria for First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children With Growth Hormone Deficiency: Do They Predict Poor Adult Height Outcome?
por: Straetemans, Saartje, et al.
Publicado: (2019)

Effect of growth hormone cotreatment in sub-fertile women ≥ 40 years: a meta-analysis
por: Elkalyoubi, Mohamed, et al.
Publicado: (2023)

The Concept of Growth Hormone Deficiency Affecting Clinical Prognosis in IVF
por: Yovich, John L., et al.
Publicado: (2019)

Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria
por: Li, Fei, et al.
Publicado: (2020)

Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients
por: Lin, Hsin-Ta, et al.
Publicado: (2022)

Cumulative live birth rates and birth outcomes after IVF/ICSI treatment cycles in young POSEIDON patients: A real-world study
por: Yan, Enqi, et al.
Publicado: (2023)

Growth hormone supplementation ameliorates blastocyst euploidy rates and improves pregnancy outcomes in women undergoing preimplantation genetic testing for aneuploidy cycles
por: Guo, Qingqing, et al.
Publicado: (2023)

Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept
por: Drakopoulos, Panagiotis, et al.
Publicado: (2020)

Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: A retrospective study according to the POSEIDON criteria
por: Farimani, Marzieh, et al.
Publicado: (2021)

Ovarian Reserve Markers in Premature Ovarian Insufficiency: Within Different Clinical Stages and Different Etiologies
por: Jiao, Xue, et al.
Publicado: (2021)

The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome
por: Humaidan, Peter, et al.
Publicado: (2016)

Androgens Profile in Blood Serum and Follicular Fluid of Women With Poor Ovarian Response During Controlled Ovarian Stimulation Reveals Differences Amongst POSEIDON Stratification Groups: A Pilot Study
por: Fuentes, Ariel, et al.
Publicado: (2019)

Correction to: Evaluation of intra-ovarian platelet-rich plasma administration on oocytes-dependent variables in patients with poor ovarian response: a retrospective study according to the POSEIDON criteria
por: Farimani, Marzieh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_10mkioc9sq02iba7il2didgpr0